EA200201011A1 - Ежедневное лечение эректильной дисфункции с использованием ингибитора фдэ5 - Google Patents
Ежедневное лечение эректильной дисфункции с использованием ингибитора фдэ5Info
- Publication number
- EA200201011A1 EA200201011A1 EA200201011A EA200201011A EA200201011A1 EA 200201011 A1 EA200201011 A1 EA 200201011A1 EA 200201011 A EA200201011 A EA 200201011A EA 200201011 A EA200201011 A EA 200201011A EA 200201011 A1 EA200201011 A1 EA 200201011A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pde5
- dysfunction
- erektile
- pde5 inhibitor
- phosphodiesterase
- Prior art date
Links
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 2
- 230000004064 dysfunction Effects 0.000 title 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 4
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Настоящее изобретение относится к ингибиторам фермента фосфодиэстеразы (ФДЭ) и к их использованию в фармацевтических изделиях. В частности, данное изобретение относится к сильнодействующим ингибиторам циклической гуанозин 3',5'-монофосфат специфичной фосфодиэстеразы 5-го типа (ФДЭ5), которая при введении в фармацевтический продукт в разовой дозированной лекарственной форме от около 1 до около 10 мг является полезной для лечения половой дисфункции посредством ежедневного введения ингибитора ФДЭ5. Промышленные изделия, описанные в этом изобретении, характеризуются ингибированием ФДЭ5 и, таким образом, приносят выгоду в тех областях терапии, в которых ингибирование ФДЭ5 является желательным, особенно эректильной дисфункции, с минимизированием или устранением неблагоприятных побочных эффектов, получающихся от ингибирования других ферментов фосфодиэстеразы, и с улучшением васкулярного состояния.Отчет о международном поиске был опубликован 2002.06.06.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/558,911 US6451807B1 (en) | 1999-04-30 | 2000-04-26 | Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor |
| PCT/US2001/012512 WO2001080860A2 (en) | 2000-04-26 | 2001-04-13 | Daily treatment for erectile dysfunction using a pde5 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200201011A1 true EA200201011A1 (ru) | 2003-06-26 |
Family
ID=24231497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200201011A EA200201011A1 (ru) | 2000-04-26 | 2001-04-13 | Ежедневное лечение эректильной дисфункции с использованием ингибитора фдэ5 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6451807B1 (ru) |
| EP (1) | EP1276481A2 (ru) |
| JP (1) | JP2003531174A (ru) |
| KR (1) | KR20030007551A (ru) |
| CN (1) | CN1446091A (ru) |
| AU (1) | AU2001253612A1 (ru) |
| BR (1) | BR0110373A (ru) |
| CA (1) | CA2407519A1 (ru) |
| CZ (1) | CZ20023577A3 (ru) |
| EA (1) | EA200201011A1 (ru) |
| HR (1) | HRP20020827A2 (ru) |
| HU (1) | HUP0300477A3 (ru) |
| IL (1) | IL152227A0 (ru) |
| MX (1) | MXPA02010539A (ru) |
| NO (1) | NO20025138L (ru) |
| NZ (1) | NZ521869A (ru) |
| PL (1) | PL360186A1 (ru) |
| SK (1) | SK15392002A3 (ru) |
| WO (1) | WO2001080860A2 (ru) |
| ZA (1) | ZA200208776B (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060222647A1 (en) * | 1993-05-27 | 2006-10-05 | Beavo Joseph A | Methods and compositions for modulating the activity of PDE5 |
| US6943166B1 (en) * | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
| MXPA00003997A (es) * | 1999-04-30 | 2002-03-08 | Lilly Icos Llc | Articulos de fabricacion. |
| MXPA02010322A (es) * | 2000-04-19 | 2004-09-10 | Univ Johns Hopkins | Metodos para la prevencion y tratamiento de trastornos gastrointestinales. |
| US8133903B2 (en) * | 2003-10-21 | 2012-03-13 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases |
| US20050048573A1 (en) * | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
| CN101106997A (zh) * | 2004-08-17 | 2008-01-16 | 约翰·霍普金斯大学 | Pde5抑制剂组合物及治疗心脏病征候的方法 |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| US7265248B1 (en) | 2005-04-29 | 2007-09-04 | Technology Innovations, Llc | Compositions and methods for the treatment of malaria |
| WO2007100387A2 (en) * | 2005-11-03 | 2007-09-07 | Dr. Reddy's Laboratories Ltd. | Process for preparing tadalafil |
| EP2705753A1 (en) | 2006-08-24 | 2014-03-12 | Surface Logix, Inc. | 2-Phenyl-imidazolotriazinone compounds as PDE5 inhibitors |
| TWI462923B (zh) * | 2010-10-18 | 2014-12-01 | Univ Kaohsiung Medical | Ｋｍｕｐ－３之心肌梗塞疾患用途 |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| JP6578046B1 (ja) * | 2018-08-23 | 2019-09-18 | Ｔｏｗａ Ｃｏｒｐｏｒａｔｉｏｎ 株式会社 | Ｐｄｅ５阻害用医薬組成物及びｐｄｅ５阻害用食品組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4931445A (en) | 1988-10-06 | 1990-06-05 | Irwin Goldstein | Agents for treatment of male impotence |
| NZ234186A (en) | 1989-07-07 | 1991-10-25 | Janssen Pharmaceutica Nv | Imidazo quinazolin-one derivatives and pharmaceutical compositions |
| DE69426804D1 (de) | 1993-05-27 | 2001-04-12 | Icos Corp | Cyclisch gmp bindende cyclisch gmp spezifische phosphodiesterase materialien und verfahren. |
| GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| GB9514465D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| GB9511220D0 (en) | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
| GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| SK154498A3 (en) | 1996-05-10 | 2000-01-18 | Icos Corp | Carboline derivatives, process for the preparation thereof, pharmaceutical compositions containing same and use of mentioned derivatives as drugs |
| US6462047B1 (en) | 1998-09-16 | 2002-10-08 | Icos Corporation | Carboline derivatives as cGMP phosphodiesterase inhibitors |
-
2000
- 2000-04-26 US US09/558,911 patent/US6451807B1/en not_active Expired - Fee Related
-
2001
- 2001-04-13 EA EA200201011A patent/EA200201011A1/ru unknown
- 2001-04-13 PL PL36018601A patent/PL360186A1/xx not_active Application Discontinuation
- 2001-04-13 KR KR1020027014383A patent/KR20030007551A/ko not_active Withdrawn
- 2001-04-13 HR HRP20020827 patent/HRP20020827A2/hr not_active Application Discontinuation
- 2001-04-13 WO PCT/US2001/012512 patent/WO2001080860A2/en not_active Ceased
- 2001-04-13 JP JP2001577959A patent/JP2003531174A/ja not_active Withdrawn
- 2001-04-13 HU HU0300477A patent/HUP0300477A3/hu unknown
- 2001-04-13 MX MXPA02010539A patent/MXPA02010539A/es unknown
- 2001-04-13 BR BR0110373-3A patent/BR0110373A/pt not_active IP Right Cessation
- 2001-04-13 NZ NZ521869A patent/NZ521869A/en unknown
- 2001-04-13 SK SK1539-2002A patent/SK15392002A3/sk unknown
- 2001-04-13 EP EP01927133A patent/EP1276481A2/en not_active Withdrawn
- 2001-04-13 IL IL15222701A patent/IL152227A0/xx unknown
- 2001-04-13 AU AU2001253612A patent/AU2001253612A1/en not_active Abandoned
- 2001-04-13 CA CA002407519A patent/CA2407519A1/en not_active Abandoned
- 2001-04-13 CN CN01811844A patent/CN1446091A/zh active Pending
- 2001-04-13 CZ CZ20023577A patent/CZ20023577A3/cs unknown
-
2002
- 2002-07-19 US US10/198,903 patent/US20030100478A1/en not_active Abandoned
- 2002-10-25 NO NO20025138A patent/NO20025138L/no not_active Application Discontinuation
- 2002-10-30 ZA ZA200208776A patent/ZA200208776B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ521869A (en) | 2004-10-29 |
| BR0110373A (pt) | 2003-02-18 |
| ZA200208776B (en) | 2003-06-03 |
| WO2001080860A2 (en) | 2001-11-01 |
| PL360186A1 (en) | 2004-09-06 |
| SK15392002A3 (sk) | 2003-03-04 |
| EP1276481A2 (en) | 2003-01-22 |
| CZ20023577A3 (cs) | 2003-06-18 |
| WO2001080860A3 (en) | 2002-06-06 |
| AU2001253612A1 (en) | 2001-11-07 |
| IL152227A0 (en) | 2003-05-29 |
| NO20025138D0 (no) | 2002-10-25 |
| HUP0300477A2 (hu) | 2003-06-28 |
| KR20030007551A (ko) | 2003-01-23 |
| HUP0300477A3 (en) | 2004-10-28 |
| CA2407519A1 (en) | 2001-11-01 |
| US6451807B1 (en) | 2002-09-17 |
| NO20025138L (no) | 2002-12-16 |
| MXPA02010539A (es) | 2003-05-14 |
| JP2003531174A (ja) | 2003-10-21 |
| US20030100478A1 (en) | 2003-05-29 |
| CN1446091A (zh) | 2003-10-01 |
| HRP20020827A2 (en) | 2004-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200000355A2 (ru) | Промышленные изделия | |
| EA200201011A1 (ru) | Ежедневное лечение эректильной дисфункции с использованием ингибитора фдэ5 | |
| GEP20094596B (en) | Compositions comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction |